Bioequivalence Study of Two Vortioxetine Formulations in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of **vortioxetine** in healthy volunteers. Bioequivalence studies are crucial in determining whether different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, ensuring therapeutic equivalence. This is clinically relevant as it ensures that patients receive the same therapeutic benefits and safety profile from different formulations of the same medication.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial population selection criteria include both genders, and the study acknowledges the inclusion of a vulnerable population. However, the sponsor has not provided specific information regarding the total number of participants. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to assess the **bioequivalence** of two formulations of vortioxetine in **healthy volunteers**. This study is structured as a Phase 2, randomized, double-blind, controlled trial. The estimated recruitment start date is January 15, 2025, with an anticipated end date of March 24, 2025. The trial will involve a series of study visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will be randomly assigned to receive one of the two formulations under investigation.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the pharmacokinetic parameters of the formulations. These visits are crucial for collecting data on the primary and secondary endpoints, which are not specified in the available data. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure participant safety and gather any remaining data.

The expected duration of participant involvement is approximately two months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are intended to ensure the collection of reliable data while maintaining participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on January 15, 2025, with an estimated end date of March 24, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The trial phase indicates a focus on evaluating the effectiveness and further safety of the intervention in a larger group of participants compared to earlier phases. The absence of specific endpoints or measurement tools in the data suggests that these details will be defined in the full trial protocol, which will guide the assessment of efficacy throughout the study duration.